Issues of drug adherence in real world clinical trials
Enabling different patient groups to understand medicine risks and benefits
Understanding how clinical diversity impacts patient centricity
Patient driven selection of clinical end points
Minimally invasive biomarker sampling
Individualising dosing of drug combinations in clinical trials
Developing effective use of statistics in clinical trial safety monitoring
New drug safety paradigms
Assessing and improving access to biosimilars in developing countries
Issues of consent in clinical trials limiting access to medicines
Building a case for redistributed pharmaceutical manufacturing
Understanding how clinical trial participation diversity impacts access to medicines
Removing barriers for access in emerging economics